Back to results
US 11,306,145 B2Granted
Binding molecules specific for FcγRIIA and uses thereof
AssigneeViela Bio, Inc.
InventorsKatherine Ann Vousden, Bo Chen, Gary Patrick Sims
Life of this patent
Estimating the term…
Abstract
The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Claims13
An isolated binding molecule that specifically binds to FcγRIIA, wherein the binding molecule comprises:
- (i) a heavy chain variable (VH) region comprising a VH-complementarity determining region (CDR)1 comprising SEQ ID NO:
- 29, VH-CDR2 comprising SEQ ID NO:
- 19, and VH-CDR3 comprising SEQ ID NO:
- 30;
- and
- (ii) a light chain variable (VL) region comprising a VL-CDR1 comprising SEQ ID NO:
- 22, VL-CDR2 comprising SEQ ID NO:
- 31, and VL-CDR3 comprising SEQ ID NO:
- 32.
6 more elements
Dependencies are inferred from the claim text.